enVVeno Medical Corp Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how enVVeno Medical Corp (NVNO) performed this year. My goal is to break down their filings so you can decide if this company fits your investment goals.

1. What does this company do?

enVVeno makes medical devices to fix "leaky" veins. Many people suffer from Chronic Venous Insufficiency (CVI), where damaged leg vein valves cause blood to pool, leading to pain, swelling, and ulcers. enVVeno is developing a replacement valve to restore healthy blood flow, specifically targeting the deep venous system, a market that currently lacks effective, long-term surgical solutions.

2. The Big Pivot: From VenoValve to enVVe

The company’s strategy shifted significantly this year. They previously focused on the VenoValve, a surgical replacement, but in August 2025, the FDA declined to approve it, citing concerns about surgical complexity and clinical data.

The company is now fully focused on their next-generation product: the enVVe System. Unlike the VenoValve, which required open surgery, enVVe is a "transcatheter" device. Doctors can implant it through a minimally invasive procedure, similar to a heart stent. By using a catheter, enVVe aims to reduce recovery times from weeks to hours, potentially serving as a disruptive technology in the vascular space.

3. Financial Performance

enVVeno is still in the development stage. For the year ending December 31, 2024, the company reported $0 in revenue. Operating expenses totaled $28.5 million, consisting of $18.2 million in research and $10.3 million in administrative costs. By year-end, the company held $12.4 million in cash. With a monthly spending rate of $2.1 million, the company will need to raise additional capital to reach its 2026 trial goals.

4. The Regulatory Gauntlet

The company’s success depends on the FDA. Because they are developing a high-risk implant, the approval process is demanding. They have finished pre-clinical testing for enVVe and are in discussions with the FDA to start a "pivotal trial" in 2026. This trial is expected to enroll 150 to 200 patients at 20-30 sites to prove the device is safe and effective.

5. Key Risks

• Regulatory Risk: The FDA might not approve enVVe. If the trial fails to show clear benefits, the business could stall permanently.
• Cash and Dilution: With $12.4 million in cash, the company will likely issue more shares to raise money. This reduces your ownership percentage. In 2024, shares outstanding increased by 15%, and further dilution is expected as they fund the trial.
• No "Plan B": The company stopped work on the VenoValve and wrote off those assets. Their entire value now rests solely on the success of the enVVe system.
• Market Adoption: Even if approved, they must prove to insurers and hospitals that enVVe is a superior alternative to compression stockings or invasive surgery.

6. Future Outlook

The company is moving toward a 2026 trial start. Management’s primary goal for the next year is to secure FDA approval to begin the study. Strong data could lead to a final approval submission by 2028. If the data is weak or they cannot raise enough money, they may be forced to sell the company or face bankruptcy.

Investor Takeaway: enVVeno is a high-risk, high-reward "all-in" bet on the enVVe system. Because they have no revenue and limited cash, your investment is essentially funding their upcoming clinical trial. Before buying, consider whether you are comfortable with the high likelihood of share dilution and the binary nature of FDA approval outcomes.